Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Erika von Euw"'
Autor:
Enrique Podaza, Ibel Carri, Mariana Aris, Erika von Euw, Alicia Inés Bravo, Paula Blanco, Juan Manuel Ortiz Wilczyñski, Daniel Koile, Patricio Yankilevich, Morten Nielsen, José Mordoh, María Marcela Barrio
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The CSF-470 vaccine consists of lethally-irradiated allogeneic cells derived from four cutaneous melanoma cell lines administered plus BCG and GM-CSF as adjuvants. In an adjuvant phase II study vs. IFN-α2b, the vaccine significantly prolonged the di
Externí odkaz:
https://doaj.org/article/8566c44582ab4163a12b6169f269e3dc
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Autor:
Mohammad Atefi, Erika von Euw, Narsis Attar, Charles Ng, Connie Chu, Deliang Guo, Ramin Nazarian, Bartosz Chmielowski, John A Glaspy, Begonya Comin-Anduix, Paul S Mischel, Roger S Lo, Antoni Ribas
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e28973 (2011)
The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progres
Externí odkaz:
https://doaj.org/article/f5dd53cf6f154f0b8e16f8e436c784c9
Autor:
Begoña Comin-Anduix, Hooman Sazegar, Thinle Chodon, Douglas Matsunaga, Jason Jalil, Erika von Euw, Helena Escuin-Ordinas, Robert Balderas, Bartosz Chmielowski, Jesus Gomez-Navarro, Richard C Koya, Antoni Ribas
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12711 (2010)
The effects on cell signalling networks upon blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4) using the monoclonal antibody tremelimumab were studied in peripheral blood mononuclear cell (PBMC) samples from patients with metastatic mel
Externí odkaz:
https://doaj.org/article/d7329642d3d84e15b0ee700bc793b3d5
Autor:
Dennis J. Slamon, Colleen Mockbee, Sara Hurvitz, Erika von Euw, Ondrej Kalous, Christophe Marchal, Ann Mc Nulty, Josh Thomas, Kevin Chau, Tong Luo, Richard Beckmann, Dylan Conklin, Neil O'Brien
Whole exome sequencing analysis of a panel of 44 breast cancer cell lines, enriched for somatic alterations with functional consequence in cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ceaad6a7dbd0936e5285def17f13c8
https://doi.org/10.1158/1535-7163.22510075
https://doi.org/10.1158/1535-7163.22510075
Autor:
Dennis J. Slamon, Colleen Mockbee, Sara Hurvitz, Erika von Euw, Ondrej Kalous, Christophe Marchal, Ann Mc Nulty, Josh Thomas, Kevin Chau, Tong Luo, Richard Beckmann, Dylan Conklin, Neil O'Brien
The cyclinD:CDK4/6:Rb axis is dysregulated in a variety of human cancers. Targeting this pathway has proven to be a successful therapeutic approach in ER+ breast cancer. In this study, in vitro and in vivo preclinical breast cancer models were used t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4d4dd18ca8f68088a433e5cedb39f3
https://doi.org/10.1158/1535-7163.c.6539497.v1
https://doi.org/10.1158/1535-7163.c.6539497.v1
Autor:
Dennis J. Slamon, Colleen Mockbee, Sara Hurvitz, Erika von Euw, Ondrej Kalous, Christophe Marchal, Ann Mc Nulty, Josh Thomas, Kevin Chau, Tong Luo, Richard Beckmann, Dylan Conklin, Neil O'Brien
Abemaciclib induces cell cycle arrest but not cell death in Rb-intact breast cancer cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb34ee1cc52efdfb7a2ecc45ac089c3
https://doi.org/10.1158/1535-7163.22510096
https://doi.org/10.1158/1535-7163.22510096
Autor:
Dennis J. Slamon, Colleen Mockbee, Sara Hurvitz, Erika von Euw, Ondrej Kalous, Christophe Marchal, Ann Mc Nulty, Josh Thomas, Kevin Chau, Tong Luo, Richard Beckmann, Dylan Conklin, Neil O'Brien
File containing three supplemental tables listing the mean tumor volumes and responses in the ER+/HER2-, HER2+/ER+ and TNBC xenografts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533a2c9b80eef8645b41366f559b52d5
https://doi.org/10.1158/1535-7163.22510069
https://doi.org/10.1158/1535-7163.22510069
Autor:
Dennis J. Slamon, John A. Glaspy, Meghan Brennan, Lisa Yonemoto, Diego Martinez, Megan M. Price, Erika Von Euw, Neil O'Brien, Richard S. Finn, Bartosz Chmielowski, Jonathan Goldman, J. Randolph Hecht, Kelly E. McCann, Gottfried E. Konecny, Arun S. Singh, Zev A. Wainberg
Supplemental Table 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::817e760041b48e5fd6a19f04b9c541cf
https://doi.org/10.1158/1078-0432.22488357
https://doi.org/10.1158/1078-0432.22488357
Autor:
Dennis J. Slamon, John A. Glaspy, Meghan Brennan, Lisa Yonemoto, Diego Martinez, Megan M. Price, Erika Von Euw, Neil O'Brien, Richard S. Finn, Bartosz Chmielowski, Jonathan Goldman, J. Randolph Hecht, Kelly E. McCann, Gottfried E. Konecny, Arun S. Singh, Zev A. Wainberg
Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a4fe0e3ea729c282091b326bb21e4ae
https://doi.org/10.1158/1078-0432.22488366.v1
https://doi.org/10.1158/1078-0432.22488366.v1
Autor:
Dennis J. Slamon, John A. Glaspy, Meghan Brennan, Lisa Yonemoto, Diego Martinez, Megan M. Price, Erika Von Euw, Neil O'Brien, Richard S. Finn, Bartosz Chmielowski, Jonathan Goldman, J. Randolph Hecht, Kelly E. McCann, Gottfried E. Konecny, Arun S. Singh, Zev A. Wainberg
Supplemental Table 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89786085b5a97f6e0a3db2084d5f1d20
https://doi.org/10.1158/1078-0432.22488360
https://doi.org/10.1158/1078-0432.22488360